Literature DB >> 15234816

A simplified plaque assay for respiratory syncytial virus--direct visualization of plaques without immunostaining.

Jennifer L McKimm-Breschkin1.   

Abstract

Due to their generally small size, detection of respiratory syncytial virus (RSV) plaques commonly relies on immunostaining using either polyclonal antisera or a pool of monoclonal antibodies against the surface fusion glycoprotein. Disadvantages include the costs of the antibodies and substrate, and microscopic examination is often needed for counting of plaques. By optimizing many parameters, greatly improved plaque assays for RSV A2, Long and RSV B 18537 strains using Vero or HEp-2 cells have been developed. Although many groups use Vero cells for plaquing, after optimization plaques were much larger in HEp-2 cells. Both cell types needed to be confluent at infection and agarose was more suitable than carboxymethyl cellulose for the overlay. Overlay medium for HEp-2 was DMEM/F12, 0.3% agarose, and for Veros it was Liebovitz L15, 5% fetal calf serum, 0.3-0.5% agarose. After 5-7 days, monolayers were fixed with 1% formal saline overnight, agarose was removed and monolayers were stained with 0.05% neutral red in water. Plaques were readily visible by eye and plates could be dried and stored permanently. Parainfluenza virus type 3 also formed large plaques in HEp-2 cells under the conditions optimal for RSV.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234816     DOI: 10.1016/j.jviromet.2004.02.020

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  28 in total

1.  Resveratrol-mediated gamma interferon reduction prevents airway inflammation and airway hyperresponsiveness in respiratory syncytial virus-infected immunocompromised mice.

Authors:  Na Zang; Xiaohong Xie; Yu Deng; Shengde Wu; Lijia Wang; Caijing Peng; Simin Li; Ke Ni; Yan Luo; Enmei Liu
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  Pathogenesis, Humoral Immune Responses, and Transmission between Cohoused Animals in a Ferret Model of Human Respiratory Syncytial Virus Infection.

Authors:  Karen L Laurie; Patrick C Reading; Kok Fei Chan; Louise A Carolan; Julian Druce; Keith Chappell; Daniel Watterson; Paul Young; Daniil Korenkov; Kanta Subbarao; Ian G Barr
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

3.  Phosphatidylinositol inhibits respiratory syncytial virus infection.

Authors:  Mari Numata; Pitchaimani Kandasamy; Yoji Nagashima; Rachel Fickes; Robert C Murphy; Dennis R Voelker
Journal:  J Lipid Res       Date:  2015-01-05       Impact factor: 5.922

4.  An Epitope-Specific Respiratory Syncytial Virus Vaccine Based on an Antibody Scaffold.

Authors:  Xiaozhou Luo; Tao Liu; Ying Wang; Haiqun Jia; Yuhan Zhang; Dawna Caballero; Juanjuan Du; Rongsheng E Wang; Danling Wang; Peter G Schultz; Feng Wang
Journal:  Angew Chem Int Ed Engl       Date:  2015-10-05       Impact factor: 15.336

5.  Limited type I interferons and plasmacytoid dendritic cells during neonatal respiratory syncytial virus infection permit immunopathogenesis upon reinfection.

Authors:  Stephania A Cormier; Bishwas Shrestha; Jordy Saravia; Greg I Lee; Li Shen; John P DeVincenzo; Young-In Kim; Dahui You
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

6.  Differential expression of cytokine transcripts in neonatal and adult ovine alveolar macrophages in response to respiratory syncytial virus or toll-like receptor ligation.

Authors:  Sasha J Fach; Alicia Olivier; Jack M Gallup; Theresa E Waters; Mark R Ackermann; Howard D Lehmkuhl; Randy E Sacco
Journal:  Vet Immunol Immunopathol       Date:  2010-02-13       Impact factor: 2.046

7.  Phosphatidylglycerol provides short-term prophylaxis against respiratory syncytial virus infection.

Authors:  Mari Numata; Yoji Nagashima; Martin L Moore; Karin Z Berry; Mallory Chan; Pitchaimani Kandasamy; R Stokes Peebles; Robert C Murphy; Dennis R Voelker
Journal:  J Lipid Res       Date:  2013-06-06       Impact factor: 5.922

8.  Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection.

Authors:  Mari Numata; Hong Wei Chu; Azzeddine Dakhama; Dennis R Voelker
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

9.  Quantitative proteomic analysis of A549 cells infected with human respiratory syncytial virus.

Authors:  Diane C Munday; Edward Emmott; Rebecca Surtees; Charles-Hugues Lardeau; Weining Wu; W Paul Duprex; Brian K Dove; John N Barr; Julian A Hiscox
Journal:  Mol Cell Proteomics       Date:  2010-07-20       Impact factor: 5.911

10.  (S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection.

Authors:  Blake P Moore; Dong Hoon Chung; Daljit S Matharu; Jennifer E Golden; Clinton Maddox; Lynn Rasmussen; James W Noah; Melinda I Sosa; Subramaniam Ananthan; Nichole A Tower; E Lucile White; Fuli Jia; Thomas E Prisinzano; Jeffrey Aubé; Colleen B Jonsson; William E Severson
Journal:  J Med Chem       Date:  2012-10-16       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.